Loading...

PHAT PHATHOM PHARMACEUTICALS INC Operational Disruptions 8-K Filing

PHTH

PHT

PHATHOM PHARMACEUTICALS INC

(PHAT)

2023 8-K

Show Summary

Show Summary

Other Special Situation

Pre-Market Approval

Financial Statements

Director Appointment

Financial Results

Earnings Report

Financial Results

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Other Special Situation

Bylaws Amendment

Loan Agreement Amendment

FDA Acceptance of New Drug ...

Financial Results Announcement

FDA Approval for VOQUEZNA T...

FDA Stability Data Submission

Financial Results Announcement

Stock Option Exchange

Stock Option Exchange

FDA Acknowledges NDA Resubm...

Annual Meeting and Changes ...

Underwriting Agreement

Resubmission of New Drug Ap...

Financial Results Announcement

Regulatory Update

Financial Results Announcement

Positive Study Results for ...

External Links:

Phathom Pharmaceuticals has submitted stability data to the FDA for its reformulated vonoprazan tablets, satisfying the FDA's request for additional data and bringing the drug closer to regulatory approval for the treatment of Erosive GERD.

AI Assistant

PHATHOM PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.